

Chemistry Testing Update

EFFECTIVE FEBRUARY 8, 2022 SARS-COV-2 ANTIBODY TESTING UPDATE

Effective February 8, 2022, Wisconsin Diagnostic Laboratories (WDL) will convert to the Roche total antibody tests for SARS-CoV-2 nucleocapsid and spike antibodies: SARS-CoV-2 Total Antibody, Nucleocapsid and SARS-CoV-2 Total Ab Quantitative Spike.

The Roche SARS-CoV-2 Total Antibody, Nucleocapsid test detects predominantly IgG, but also IgM and IgA, antibodies produced against either the nucleocapsid protein or receptor binding domain (RBD) of the spike protein. For best results, it is recommended that testing be performed 14 days or more after onset of symptoms.

The Roche SARS-CoV-2 Total Antibody Quantitative Spike assay is semi-quantitative and will be reported qualitatively and with a semi-quantitative concentration. Of note, the clinical applicability of the semiquantitative results is currently unknown. Additionally, SARS-CoV-2 spike assays are not standardized and, thus, the reported semi-quantitative concentrations are not comparable between different vendors' assays.

Fact Sheets for Healthcare Providers or Recipients can be found on the FDA website https:// www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medicaldevices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2 by searching for "Roche" in the table of assays and under the "Authorization Documents" column.

Test Information:

Test Name	Mnemonic	Test Code	Epic Code	CPT Code	Components
SARS-CoV-2 Total Antibody, Nucleocapsid	COVID AB TOT	12304307	LAB9333	86769	Covid Total Antibodies
SARS-CoV-2 Total Antibody Quantitative Spike	Covid Total QT	12304292	LAB9397	86769	COVID TOTAL Spike COVID TOTAL Spike QT

For Technical Questions or Additional Information, Please Contact:

Laura Smy, PhD, MLS, Director of Clinical Chemistry and Toxicology, 414.805.6975 or Lsmy@mcw.edu





